Evidence map›Paper›PMID 31673144›Full record

SynthesisThe pharmacogenomics journal2020

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.

Masanobu Takeuchi, Tohru Kobayashi, Tina Biss, Farhad Kamali, Susan I Vear, Richard H Ho, Fanny Bajolle, Marie-Anne Loriot, Kaitlyn Shaw, Bruce C Carleton and 10 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The pharmacogenomics journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Influence ofCardiovascular therapeutics · 2021
    Pooled it
  2. Pharmacogenetics in pediatric cardiology.Frontiers in pediatrics · 2026
    Article
  3. Observational
  4. Review
  5. Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  6. [The Effect ofSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021
    Article
  7. Genes · 2020
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 6 countries.

Masanobu TakeuchiDivision of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada.
Tohru KobayashiDivision of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada.
Tina BissInstitute of Cellular Medicine, Newcastle University and Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, UK.
Farhad KamaliInstitute of Cellular Medicine, Newcastle University and Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, UK.
Susan I VearDivision of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH, US.
Richard H HoDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN, US.
Fanny BajolleAssistance Publique Hôpitaux de Paris, Hôpital Necker Enfants Malades, Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Centre de référence M3C, Paris, France.
Marie-Anne LoriotUniversité Paris Descartes, Inserm Unité Mixte de Recherche (UMR)-S, Paris, France.
Kaitlyn ShawInfluenza and Emerging Respiratory Pathogens, BC Centre for Disease Control, Vancouver, BC, Canada.
Bruce C CarletonDivision of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Anna-Karin HambergDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Mia WadeliusDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-6368-2622
Keiichi HironoDepartment of Pediatrics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Masato TaguchiGraduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Takuya WakamiyaDepartment of Pediatrics, Yokohama City University, School of Medicine, Yokohama, Kanagawa, Japan.
Masakatsu YanagimachiDepartment of Pediatrics, Yokohama City University, School of Medicine, Yokohama, Kanagawa, Japan.
Keita HiraiDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.ORCID http://orcid.org/0000-0001-8027-3508
Kunihiko ItohDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Leonardo R BrandãoDivision of Pediatric Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Shinya ItoDivision of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada. shinya.ito@sickkids.ca.
Hospital for Sick Children · CADélégation Paris 5 · FRNewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversity of Shizuoka · JPUniversity of Toyama · JPUppsala University · SEBC Centre for Disease Control · CAKanagawa Children's Medical Center · JPMonroe Carell Jr. Children's Hospital · USNationwide Children's Hospital · USTokyo Medical and Dental University · JPUniversity of British Columbia · CA

Funding

Hepatic OATP Drug Transporters and Chemotherapy DispositionR01GM099924 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HO, RICHARD HSINSHIN · 2012 to 2017
$2.0M
6 · The paper itself

Abstract

Studies on the effect of cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) polymorphisms on warfarin maintenance dose in children are conflicting. We conducted a systematic review and meta-analysis to evaluate the effect of these polymorphisms on warfarin maintenance dose in children. We searched relevant literature using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trial libraries without any language restrictions from their inception to 23 July 2017. Dose differences are expressed as standardized mean difference (SMD) or mean difference (MD) with 95% confidence intervals (CI). This review was registered in the PROSPERO prospective register of systematic reviews (CRD42015016172). We included a total of nine studies (745 participants) in the meta-analysis. Patients with CYP2C9 *1/*2, *1/*3, *2/*2, *2/*3, or *3/*3 required a lower warfarin maintenance dose compared with patients with CYP2C9 *1/*1 (SMD = -0.610, 95% CI: -0.802 to -0.419, I

Indexed as

AnticoagulantsChildCross-Sectional StudiesCytochrome P-450 CYP2C9Cytochrome P450 Family 4HumansMaintenance ChemotherapyObservational Studies as TopicPolymorphism, Single NucleotideVitamin K Epoxide ReductasesWarfarinAnticoagulantsCYP2C9 protein, humanCYP4F2 protein, humanCytochrome P-450 CYP2C9Cytochrome P450 Family 4Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID31673144
OpenAlexW2982481126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.